Moderna takes on a low-risk pact with CAR-T player Autolus for mRNA-based cancer drugs

Kyle Blankenship

Moderna’s Covid-19 vaccine has transformed the once-backwater biotech into one of the most highly valued drugmakers in the world in the span of a year …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Moderna takes on a low-risk pact with CAR-T player Autolus for mRNA-based cancer drugs

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

At least seven drugmakers say they will participate in round two of IRA negotiations

Can Bill Anderson save Bayer?

How AI can address ongoing challenges in the life sciences industry

Mod­er­na takes on a low-risk pact with CAR-T play­er Au­to­lus for mR­NA-based can­cer drugs

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Moderna takes on a low-risk pact with CAR-T player Autolus for mRNA-based cancer drugs